HealthPartners has announced that it is recruiting 1,500 Minnesota adults to participate in a Phase 3 study of a vaccine candidate developed by AstraZeneca. A Star Tribune article details the goals of the vaccine study, how the proposed vaccine is supposed to work, and how a vaccine may be distributed once it is approved. The article includes insights provided in the Consortium’s recent “COVID Vaccine Research & Deployment: Reconciling Speed & Safety” webinar. Dr. Margaret Hamburg warns that political interference may “undermine confidence and trust,” while Dr. Nicole Lurie explains that continued vaccine development and improvement will likely continue even after a vaccine becomes available. Read the full Star Tribune article here.
Thursday, September 3, 2020